{"id":"W2948813200","doi":"10.1186/s13075-019-1917-8","title":"Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry","year":2019,"lang":"en","type":"article","venue":"Arthritis Research & Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"ca_institutions":"Osteoporosis Canada; Montreal Clinical Research Institute","funders":"UCB; Sandoz; Celgene; Roche; Novartis; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb; AbbVie; Sanofi; Merck","keywords":"Abatacept; Golimumab; Medicine; Etanercept; Adalimumab; Infliximab; Certolizumab pegol; Rheumatoid arthritis; Discontinuation; Internal medicine; Hazard ratio; Persistence (discontinuity); Proportional hazards model; Tumor necrosis factor alpha; Confidence interval; Rituximab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.001993617,0.0002059051,0.0007328003,0.0001496661,0.0001586977,0.00006114811,0.0004201192,0.0001238081,0.0007149011],"category_scores_gemma":[0.0007094706,0.0001202698,0.0001275104,0.0004081393,0.002974533,0.0002520024,0.0001244102,0.0003896013,0.00000863381],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002541071,"about_ca_system_score_gemma":0.0002812463,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002798775,"about_ca_topic_score_gemma":0.003350725,"domain_scores_codex":[0.9964886,0.0008903167,0.0007781588,0.000530941,0.0008406949,0.000471253],"domain_scores_gemma":[0.9948345,0.003625441,0.0001869013,0.0009936674,0.0002015044,0.0001579634],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.004649464,0.001623019,0.5399196,0.00006717082,0.0002847931,0.0002124272,0.03237719,4.135664e-7,0.02422913,0.0002968396,0.00104299,0.395297],"study_design_scores_gemma":[0.04018322,0.03295732,0.6084546,0.006873129,0.000004044699,0.0004471829,0.1104924,0.0001045979,0.04702817,0.001026394,0.1517975,0.0006314779],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8762658,0.1214443,6.829824e-7,0.0006352324,0.00005140871,0.001215102,0.0003094297,0.0000078895,0.00007022377],"genre_scores_gemma":[0.5359732,0.4637644,0.00006756435,0.00003654174,0.00002176459,0.00006368493,0.00003812291,0.00001097169,0.00002379219],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3946655,"threshold_uncertainty_score":0.9997388,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1015715077618527,"score_gpt":0.3879436399079944,"score_spread":0.2863721321461417,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}